NCT06872112RecruitingPhase 1
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
Source: ClinicalTrials.gov · Last updated 23 Apr 2026
Brief summary (registry, in English)
This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 6 Mar 2025
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Jan 2029
- Lead sponsor
- Joseph C. Wu
- NCT number
- NCT06872112
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 15
- From 1 Apr 2026 to the primary completion date, 1 Jan 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with serious concomitant morbidity per investigator assessment.
Other
- Participants who meet any of the following criteria will be excluded from the study.
Who the study is looking for
- Each participant must meet the following criteria to be enrolled in this study:
- Adults aged 18 to 75 years.
- WHO functional class I, II/III despite treatment with maximally tolerated doses of 2 or more treatment modalities including PDE5 inhibitors, guanylate cyclase stimulators, endothelin receptor antagonists, and prostanoids when appropriate.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stanford University Coordinator of this site? Confirm its status | Stanford | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.